Eyal Melamed

Ovuline, Inc. designs and develops applications for women?s health. It designed two applications, Ovia Fertility and Ovia Pregnancy, to track women?s fertility and pregnancy and also provide users with a feedback loop for their symptoms. The company was founded by Alex Baron and Paris Wallace in June, 2012 and is headquartered in Boston, MA.

Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey.

Creo Products, Inc. develops applications for imaging and information technology. The private company is based in Burnaby, Canada. and has subsidiaries in Canada. The Canadian company was founded by Ken Spencer. Ken Spencer has been the CEO since incorporation.

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

Part of Hancom, Inc., Software Imaging Technology Ltd. provides mobile printing services. The company is based in Oxford, UK. Software Imaging Technology was acquired by Hancom, Inc. on April 10, 2013 for $0.89 million.

Cobro Ventures, Inc. ( Cobro Ventures ) is a venture capital firm founded in 2013 by Marc A. Cohen. The firm is headquartered in Arlington, Virginia.

Rythm SAS develops a device which helps to monitor and analyze the sleep. Its product, Dreem, is a sleep solution that monitors, analyzes, and acts on brain to enhance sleep. The company was founded by Hugo Mercier and Quentin Soulet de Brugière in 2014 and is headquartered in Paris, France.

HiDoc Technologies GmbH develops a platform which enables patients to take control of their digestive health through smart mobile applications. The company was founded by Andre Sommer, Dankrad Feist, Jesaja Brinkmann and Orest Tarasiuk in 2016 and is headquartered in Berlin, Germany.

Platform Science, Inc. engages in the development and integration of hardware and software solutions for the transportation industry. Its digital supply chain technology enables customers and developers to unlock transportation data. The company was founded by Jake Fields and Jack Kennedy in 2015 and is headquartered in San Diego, CA.

Solenic Medical, Inc. operates as a medical device company. It develops and commercializes a method for preventing prosthetic joint infection (PJI) based on technology. The firm?s technology offers an apparatus for the eradication of biofilm from metallic implants. The company was founded by David Greenberg and Rajiv Chopra in 2019 and is headquartered in College Station, TX.

Bublup, Inc. engages in the development of a cloud platform for saving photos and documents. The company was founded on December 27, 2011 and is headquartered in Arlington, VA.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023.